Full Press Release Details
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
Thomas Dittrich Returning to Amgen as CFO
THOUSAND OAKS, Calif. (May 19, 2026) – Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020. The company also announced that Thomas Dittrich will return to Amgen as executive vice president on July 1 and succeed Griffith as chief financial officer effective September 1, 2026.
“We are grateful to Peter for his leadership and lasting impact on the company,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “Peter has helped position Amgen to deliver attractive long-term growth and expand our ability to serve patients in the years ahead.”
During his tenure, Griffith strengthened the company's financial foundation, supported disciplined capital allocation and helped advance Amgen's long-term growth strategy across the business.
Dittrich, who previously held senior finance roles at Amgen, brings more than 30 years of international leadership experience to the company, along with a strong understanding of the biopharmaceutical industry and consumer-focused healthcare markets. Most recently, he served as chief financial officer of Galderma. Prior to that, he served as chief financial officer at both Shire and Sulzer. Dittrich will oversee all aspects of Amgen's financial operations. Griffith will remain with the company into January 2027 to support a seamless transition.
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of